The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tamsulon     5-[(2R)-2-[2-(2- ethoxyphenoxy)ethylamino]p...

Synonyms: Flomaxtra, Flowmax, Flomax, Harnal, TAMSULOSIN, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07124


Psychiatry related information on C07124


High impact information on C07124

  • CONCLUSION: These results suggest that although the alpha1-adrenergic receptor-blocking effect of tamsulosin on blood vessels is relatively small, it is clearly correlated with plasma drug concentration and a higher dose of the drug could cause systemic adverse effects [7].
  • Tamsulosin concentrations in the aqueous humor and serum were analyzed [8].
  • Tamsulosin concentrations varied between 0.1 and 1.0 ng/mL in the anterior chamber fluid [8].
  • RESULTS: Each patient administered tamsulosin had a sluggish hypotonic iris, along with a tendency toward miosis and a tendency for prolapse of the iris into the phaco tunnel or into the side port during cataract surgery [8].
  • CONCLUSIONS: Tamsulosin has selective alpha1A-adrenoreceptor antagonistic properties and obviously binds for a long period to the postsynaptic nerve endings of the iris dilator muscle, thus affecting iris dilatation and leading to complications in cataract surgery [8].

Chemical compound and disease context of C07124


Biological context of C07124


Anatomical context of C07124

  • Tamsulosin: an update of its role in the management of lower urinary tract symptoms [3].
  • Tamsulosin is the first subtype-selective (alpha IA) alpha 1 adrenoceptor antagonist with specificity for prostatic alpha 1 adrenoceptors (alpha 1A adrenoceptors are thought to be involved in prostatic smooth muscle contraction) to become available for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) [2].
  • MATERIALS AND METHODS: A total of 60 consecutive symptomatic patients with stones located in the juxtavesical tract of the ureter were randomly divided into group 1--30 who received oral floroglucine-trimetossibenzene 3 times daily and group 2--30 who received 0.4 mg tamsulosin daily [17].
  • PURPOSE: We evaluated the efficacy and safety of tamsulosin in patients with neurogenic lower urinary tract dysfunction secondary to suprasacral spinal cord lesions in a 4-week randomized controlled trial (RCT) followed by a 1-year, open label, long-term study [18].
  • Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats [19].

Associations of C07124 with other chemical compounds


Gene context of C07124

  • 4. It is concluded that formation of tamsulosin metabolites, AM-1 and M-1, is catalysed by CYP3A4 whereas that of M-3 and M-4 is catalysed by CYP2D6 [24].
  • Comparison of the affinities of these alpha-1-adrenoceptor antagonists at the cloned alpha-1a, alpha-1b and alpha-1d-adrenoceptor subtypes revealed that tamsulosin and 5-Me-urapidil showed selectivity for the alpha-1a subtype [25].
  • We conclude that most tamsulosin metabolites are high potency antagonists at the alpha-1 adrenoceptors and retain the alpha-1A over the alpha-1B adrenoceptor selectivity of tamsulosin [26].
  • 3. At the alpha 1B-adrenoceptor of the rat spleen and rabbit corpus cavernosum penis, tamsulosin again acted as a competitive antagonist but with a significantly lower affinity (pKB = 8.9-9.2) [27].
  • The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes [27].

Analytical, diagnostic and therapeutic context of C07124

  • Tamsulosin is available as a controlled release formulation suitable for once daily administration; dose titration is not required [2].
  • Tamsulosin 0.4 and 0.8 mg/day in a modified-release formulation was significantly more effective than placebo in large (n >250) double-blind, randomised, multicentre, 12- to 13- week clinical trials in patients with LUTS [3].
  • With the exception of a numberically greater incidence of abnormal ejaculation, dizziness and rhinitis, the incidence of adverse events with tamsulosin 0.4 mg/day was similar to that seen with placebo in randomised, double-blind studies [3].
  • However, tamsulosin is unlikely to produce orthostatic hypotensive adverse effects or interfere with concomitant antihypertensive drug therapy [3].
  • Moreover, 12, 18, and 24 h after the oral administration of KMD-3213, a dose-dependent inhibition of the IUP response was found, whereas the effect of tamsulosin disappeared at 18 h after the oral administration [28].


  1. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Kyprianou, N., Benning, C.M. Cancer Res. (2000) [Pubmed]
  2. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Wilde, M.I., McTavish, D. Drugs (1996) [Pubmed]
  3. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Lyseng-Williamson, K.A., Jarvis, B., Wagstaff, A.J. Drugs (2002) [Pubmed]
  4. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. van Dijk, M.M., de la Rosette, J.J., Michel, M.C. Drugs (2006) [Pubmed]
  5. Medical therapy for benign prostatic hyperplasia: a review of the literature. Clifford, G.M., Farmer, R.D. Eur. Urol. (2000) [Pubmed]
  6. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain. Batista, J.E., Palacio, A., Torrubia, R., Hernández, C., Vicente, J., Resel, L. Arch. Esp. Urol. (2002) [Pubmed]
  7. Antagonistic activity of tamsulosin against human vascular alpha1-adrenergic receptors. Harada, K., Kawaguchi, A., Ohmori, M., Fujimura, A. Clin. Pharmacol. Ther. (2000) [Pubmed]
  8. Influence of tamsulosin on the iris and its implications for cataract surgery. Pärssinen, O., Leppänen, E., Keski-Rahkonen, P., Mauriala, T., Dugué, B., Lehtonen, M. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  9. Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues. Amadesi, S., Varani, K., Spisani, L., Daniele, C., Turini, A., Agnello, G., Zamboni, P., Borea, P.A., Geppetti, P. Prostate (2001) [Pubmed]
  10. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Elshaikh, M.A., Ulchaker, J.C., Reddy, C.A., Angermeier, K.W., Klein, E.A., Chehade, N., Altman, A., Ciezki, J.P. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  11. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Partin, J.V., Anglin, I.E., Kyprianou, N. Br. J. Cancer (2003) [Pubmed]
  12. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. Dellabella, M., Milanese, G., Muzzonigro, G. J. Urol. (2005) [Pubmed]
  13. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Höfner, K., Claes, H., De Reijke, T.M., Folkestad, B., Speakman, M.J. Eur. Urol. (1999) [Pubmed]
  14. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. Sato, S., Ohtake, A., Matsushima, H., Saitoh, C., Usuda, S., Miyata, K. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  15. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. Rossi, C., Kortmann, B.B., Sonke, G.S., Floratos, D.L., Kiemeney, L.A., Wijkstra, H., de la ROSETTE, J.J. J. Urol. (2001) [Pubmed]
  16. Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. Morishima, S., Tanaka, T., Yamamoto, H., Suzuki, F., Akino, H., Yokoyama, O., Muramatsu, I. J. Urol. (2007) [Pubmed]
  17. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. Dellabella, M., Milanese, G., Muzzonigro, G. J. Urol. (2003) [Pubmed]
  18. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. Abrams, P., Amarenco, G., Bakke, A., Buczyński, A., Castro-Diaz, D., Harrison, S., Kramer, G., Marsik, R., Prajsner, A., Stöhrer, M., Van Kerrebroeck, P., Wyndaele, J.J. J. Urol. (2003) [Pubmed]
  19. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. Yokoyama, O., Yusup, A., Oyama, N., Aoki, Y., Miwa, Y., Akino, H. J. Urol. (2007) [Pubmed]
  20. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. Leonardi, A., Hieble, J.P., Guarneri, L., Naselsky, D.P., Poggesi, E., Sironi, G., Sulpizio, A.C., Testa, R. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  21. Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. Hancock, A.A., Brune, M.E., Witte, D.G., Marsh, K.C., Katwala, S., Milicic, I., Ireland, L.M., Crowell, D., Meyer, M.D., Kerwin, J.F. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  22. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. Tatemichi, S., Akiyama, K., Kobayashi, M., Yamazaki, Y., Yokoyama, O., Uruno, T. J. Urol. (2006) [Pubmed]
  23. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. Athanasopoulos, A., Gyftopoulos, K., Giannitsas, K., Fisfis, J., Perimenis, P., Barbalias, G. J. Urol. (2003) [Pubmed]
  24. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Kamimura, H., Oishi, S., Matsushima, H., Watanabe, T., Higuchi, S., Hall, M., Wood, S.G., Chasseaud, L.F. Xenobiotica (1998) [Pubmed]
  25. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. Martin, D.J., Lluel, P., Guillot, E., Coste, A., Jammes, D., Angel, I. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  26. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. Taguchi, K., Saitoh, M., Sato, S., Asano, M., Michel, M.C. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  27. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Noble, A.J., Chess-Williams, R., Couldwell, C., Furukawa, K., Uchyiuma, T., Korstanje, C., Chapple, C.R. Br. J. Pharmacol. (1997) [Pubmed]
  28. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. Akiyama, K., Hora, M., Tatemichi, S., Masuda, N., Nakamura, S., Yamagishi, R., Kitazawa, M. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
WikiGenes - Universities